Reply to "Keynote 48: Is it really for everyone?"

Oral Oncol. 2021 Jan:112:104983. doi: 10.1016/j.oraloncology.2020.104983. Epub 2020 Oct 6.

Authors

Barbara Burtness¹, Joy Ge²

Affiliations

¹ Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA. Electronic address: barbara.burtness@yale.edu.
² Merck & Co., Inc., Kenilworth, NJ, USA.

PMID: 33032941
DOI: 10.1016/j.oraloncology.2020.104983

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Antineoplastic Agents, Immunological*
Cetuximab
Humans
Squamous Cell Carcinoma of Head and Neck

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab
Cetuximab